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Summary Polymerase chain reaction (PCR) genotyping of malaria parasites in drug efﬁcacy trials helps
differentiate reinfections from recrudescences. A combination therapy trial of one (n ¼ 115) or three
(n ¼ 117) days artesunate (1AS, 3AS 4 mg/kg/day) plus sulphadoxine–pyrimethamine (SP) vs. SP alone
(n ¼ 153) was conducted in Mbarara, a mesoendemic area of western Uganda. All paired recurrent
Plasmodium falciparum parasitaemias on days 7, 14, 21 and 28 post-treatment were genotyped by PCR
ampliﬁcation and analysis of glutamate-rich protein (glurp) and merozoite surface proteins (msp) 1 and
2 genes to distinguish recrudescent from new infections. A total of 156 (1AS ¼ 61, 3AS ¼ 35, SP
alone ¼ 60) of 199 paired recurrent samples were successfully analysed and were resolved as 79
recrudescences (1AS ¼ 32, 3AS ¼ 8, SP ¼ 39) and 77 as new infections (1AS ¼ 29, 3AS ¼ 27,
SP ¼ 21). The ratios of proportions of new to recrudescent infections were 0.2, 0.9, 1.4 and 1.9 on days
7, 14, 21 and 28, respectively (P < 0.001, v
2 test for linear trend). Unexpected high new infection rates
were observed early in follow-up on days 7 [5/26 (19.2%)] and 14 [24/51 (47.1%)]. These results
impact signiﬁcantly on resistance monitoring and point to the value of genotyping all recurrent infections
in antimalarial trials.
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Introduction
The World Health Organization (WHO) in vivo antima-
larial efﬁcacy testing protocol is instrumental in assessing
and monitoring the emergence and extent of parasite
resistance to antimalarial drugs (WHO 1973). The current
WHO in vivo protocol for high transmission areas
recommends 28 days of follow-up, stipulating that recur-
rent parasites should be genotyped by polymerase chain
reaction (PCR) to distinguish recrudescent from new
infections (WHO 2003, 2006). The ability to discriminate
newly acquired infections by comparison of baseline and
recurrent parasite genotypes allows a more accurate
estimate of the true levels of treatment failures. However,
because of resource constraints in malaria-endemic areas,
genotyping all recurrent infections, particularly in large
trials, is expensive and may not be feasible. To compensate
for such limited recourses, correction of treatment outcome
could be made by only genotyping post-day 14 recurrences
whilst assuming that most recurrent parasites before or on
day 14 are likely to be due to recrudescences. This strategy
was adopted for a series of WHO/TDR coordinated
clinical trials assessing artesunate in combination with
standard antimalarial drugs for the treatment of paediatric
falciparum malaria in several African countries, including
Burkina Faso, Gabon, The Gambia, Sao Tome ´, Senegal,
Uganda, Malawi and Kenya (von Seidlein et al. 2000;
Adjuik et al. 2002, 2004; Gil et al. 2003; Obonyo et al.
2003; Priotto et al. 2003; Sirima et al. 2003). We report
the PCR-deﬁned reinfection rates on days 7, 14, 21 and 28
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their effect on the efﬁcacy outcome.
Methodology
A 28-day antimalarial combination efﬁcacy trial was
conducted in Mbarara District Hospital in Uganda, an area
of seasonal, mesoendemic malaria using artesunate
(AS 4 mg/kg/day)/placebo plus standard dose sulphadox-
ine–pyrimethamine (SP) for treating acute uncomplicated,
falciparum malaria in children: SP alone (n ¼ 168),
SP + AS 3 days (n ¼ 126), SP + AS 1 day (n ¼ 126). The
trial proﬁle and clinical ﬁndings are detailed in Priotto
et al. (2003).
PCR ampliﬁcation
Blood for PCR analysis was collected onto Isocode stix
 
(Schleicher & Schull, Dassel, Germany) on days 0, 7, 14,
21 and 28 and DNA extracted following the manufac-
turer’s instructions (i.e. washing and boiling of Isocode
stix
 ). Plasmodium falciparum in paired samples collec-
ted on day 0 and any day (7, 14, 21 or 28) of recurrent
parasitaemia were genotyped by analysing the glurp, msp
1 and 2 loci. PCR ampliﬁcations were performed at the
Ifakara Health Research and Development Centre
(IHRDC) laboratory using an MJ Thermal Controller
PTC-100
TM (MJ Research Inc., Watertown, USA).
Primary glurp, msp1 and msp2 PCR reactions were
multiplexed whereas nested PCR ampliﬁcations were
performed separately for each locus. The primary and
nested ampliﬁcations were carried out in 20 and 30 ll
reaction volumes using 5 ll of template DNA and 2 llo f
primary PCR product, respectively. All oligonucleotide
primers and reference DNA were obtained from the
Malaria Research and Reference Reagents Resource
Centre (MR4). The oligonucleotide primers have been
described elsewhere (Felger et al. 1994; Irion et al. 1998;
Snounou et al. 1999). Temperature cycling parameters
were: initial denaturation at 94  C for 5 min followed by
30 cycles of denaturation at 94  C for 1 min, annealing at
55  C for 2 min (for primary PCR) or 58  C for 2 min
(for nested PCR) and extension at 72  C for 2 min. The
last extension cycle was prolonged for 10 min. msp2 PCR
product (10 ll) was digested with 3 U of HinfIII for 2.5 h
at 37  C and the resulting fragments were resolved on
10% polyacrylamide gels. The glurp and msp1 PCR
products were directly resolved on 2% agarose gel. For
better comparison of fragments paired samples were
loaded onto the gels side by side. Gels were stained with
ethidium bromide, visualized under UV illumination,
photographed and discrimination made as described.
Deﬁnitions of recrudescent and new infections and data
analysis
A recurrent parasitaemia was classiﬁed as a recrudescence
(true failure) if the following conditions were met: (i) all
alleles of the three loci in the baseline and recurrent
parasitaemia were identical, (ii) a sharing of baseline and
recurrent alleles but with some missing alleles in the
recurrent parasitaemia, and (iii) a sharing of baseline and
recurrent alleles but with new alleles in recurrent sample
that were not observed at baseline. A recurrent parasitae-
mia was classiﬁed as a new infection or treatment success,
if the allelic pattern for any one of the loci differed
completely between the baseline and recurrent samples
(Snounou & Beck 1998). The clinical and molecular
genotyping data were analysed using stata v 8.0 (Stata
Corporation Inc., Texas, USA)
Results
Of the 373 patients who completed the 28-day follow-up
190 had recurrent parasitaemias. All these recurrent
parasitaemias were genotyped by PCR ampliﬁcation to
distinguish recrudescence from reinfection. Table 1 pro-
vides a summary of genotyping results per treatment arm.
PCR was unresolved for 34 patients due to eight incom-
plete paired samples and failure to extract/amplify DNA on
26 recurrent samples. The proportions of new infections on
days 7, 14, 21, 28 were 5 of 26 (19.2%), 24 of 51 (47.1),
29 of 50 (58%) and 19 of 29 (65.5%), respectively. The
corresponding values for the recrudescences were 21
(80.8%), 27 (52.9%), 21 (42%), and 10 (34.5%). Figure 1
illustrates proportions of new and recrudescent infections
on days 7, 14, 21 and 28. The ratios of proportions of new
to recrudescent infections were 0.2 (19.2:80.8), 0.9
(47.1:52.9), 1.4 (58:42), and 1.9 (65.5:34.5), on days 7,
14, 21, and 28, respectively. The chi-square test for linear
trend was 12.8 (P < 0.001), demonstrating a linear
increase in the odds ratios on days 14, 21 and 28 compared
with day 7. The frequencies of new infections increased
Table 1 Distribution of recrudescences, new infections and
unresolved recurrent infections in a cohort of Ugandan children
treated for Plasmodium falciparum malaria
Genotyping status SP SP + 1AS SP + 3AS Total
Recrudescence 39 32 8 79
New infection 21 29 27 77
Unresolved 14 11 9 34
Total 74 72 44 190
SP, sulphadoxine–pyrimethamine; 1AS, 1 day artesunate; 3AS,
3 days artesunate.
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high rates on days 7 and 14. 1 The effect of the 29, pre-day
14, new infections is to lower the overall failure rate (all
three arms combined) by 7.8% (29/373) by counting
unresolved PCR data as failures, or by 8.6% (29/339), if
unresolved PCR data are excluded.
Discussion
In the artesunate-based combination therapy trials con-
ducted by WHO/TDR in Sub-Saharan African countries
only post-day 14 recurrent parasitaemias were genotyped
to distinguish recrudescent from new parasites and treat-
ment failure rates adjusted accordingly. In the present
study, we genotyped all recurrent parasitaemias observed
on days 7, 14, 21 and 28 from one site, Mbarara, Uganda,
in order to assess pre- and post-day 14 re-infection rates.
We observed unexpectedly high frequencies of genotypi-
cally new infections on days 7 (approx. 19%) and 14
(approx. 47%). Although the entomological inoculation
rate was not measured in this study, cumulative
re-inoculations during follow-up have resulted in these new
infections which represent an important fraction of the
total number of recurrent parasitaemias. Given that the
prepatent period for P. falciparum is 6–12 days, and that
pyrimethamine has weak causal prophylactic activity,
parasitaemias detected on days 7 or 14 after initial parasite
clearance may represent early new infections. Therefore,
the assumption that recurrent parasitaemias on days 7 and
14 in high transmission areas are due to recrudescence and
should be excluded from genotyping assays may be
erroneous. These ﬁndings strongly suggest that genotyping
should also be conducted on recurrent parasitaemias
recorded before and on day 14.
Characterizing these early recurrences may change sub-
stantially our appreciation of drug efﬁcacy. By taking these
new infections into account, the overall failure rate fell by
approximately 7–8%. This change could have a profound
effect on deciding drug policy if the efﬁcacy of a given drug
is not deemed to have reached a predeﬁned threshold for
changing drug policy. The using of PCR-corrected efﬁcacy
end points in malarial drug trials has become standard
practice but there are variations in the way that the PCR
data have been interpreted (Ranford-Cartwright et al.
1997; Brockman et al. 1999; Basco & Ringwald 2000;
Magesa et al. 2001; Basco et al. 2002; Cattamanchi et al.
2003; Happi et al. 2004). This calls for a standardized
genotyping protocol for areas of intense malaria trans-
mission.
It has been speculated that new infections might already
be present during the clinical presentation but sequestered
and not detected by PCR only to be picked up at the time
of recurrence. Although this might indeed occur in a few
cases, ample evidence exists that clinical episodes are less
complex. A study by Irion et al. (1998) found that <2%
of recrudescent genotypes were absent on day 0 but were
detected on day 3. Similarly, Farnert and Bjorkman
(2005) detected the same genotypes in consecutive sam-
ples obtained every 12 h for at least 3 days post-treatment
in Swedish non-immune travellers who acquired falcipa-
rum malaria in Africa. These observations suggest that
single time-point samples may reliably represent all
subpopulations present prior to treatment. A further
complication in the interpretation of paired genotype data
arises from infections with new parasites possessing
identical genotypes to those present on day 0, leading to
an erroneous diagnosis of recrudescence. However, in
endemic areas the probability of this occurrence is rather
low and negligible when two or more discriminatory
markers are being used. We believe this theoretical
possibility is not an important consideration in the
interpretation of our ﬁndings because we observed a high
rate (approx. 33%) of new infections (different geno-
types) within the ﬁrst 14 days of follow-up.
In our study, laboratory failure to amplify/detect parasite
genetic material in the recurrent samples was the main
cause of the loss of genotyping data. This PCR failure is
highly attributable to the low parasite densities in the
recurrent samples coupled with a less invasive/rigorous
DNA extraction method consisting of simple washing and
boiling of the Isocode stix
 . The performance and effective
use of PCR genotyping will be detailed in a general report
on the combination therapy trials that will be published
separately.
The deﬁnition of drug-resistant malaria and the report-
ing of drug efﬁcacy data are becoming more complicated
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Figure 1 Distribution of PCR-determined recrudescence vs. new
infections during follow-up in Ugandan children with uncompli-
cated falciparum malaria treated with either artesunate or placebo
plus standard dose sulphadoxine/pyrimethamine.
Tropical Medicine and International Health volume 12 no 2 pp 219–223 february 2007
K. Mugittu et al. Molecular genotyping in a malaria treatment trial in Uganda
ª 2007 Blackwell Publishing Ltd 221with our better understanding of P. falciparum molecular
genetics, seasonal variations in malaria transmission, drug
pharmacokinetics (e.g. longer follow-up is required for
long half-life drugs) and the intrinsic parasiticidal effects of
antimalarial drugs (White 1998). Further studies are
needed to assess the importance of genotyping recurrent
parasitaemias observed between days 7 and 14 and how
this might reﬁne the current WHO deﬁnitions of late
clinical and parasitological failures. More robust deﬁni-
tions will be beneﬁcial to policy makers.
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Ge ´notypage mole ´culaire dans une e ´tude sur le traitement de malaria en Ouganda - taux e ´leve ´ inattendu de nouvelles infections ende ´ans deux semaines
apre `s traitement
Le ge ´notypage des parasites de la malaria par la re ´action en chaı ˆne de la polyme ´rase (PCR) dans les e ´tudes sur l’efﬁcacite ´ des me ´dicaments permet de
diffe ´rencier les re ´infections des recrudescences. Un essai comparatif de la the ´rapeutique de combinaison d’un jour (1AS, n ¼ 115) ou de trois jours (3AS,
n ¼ 117) avec de l’arte ´sunate (4 mg/kg/jour) plus du sulfadoxine-pyrime ´thamine (SP) contre le traitement a ` base de SP seul (n ¼ 153) a e ´te ´ conduit a `
Mbarara, une re ´gion me ´so ende ´mique de l’ouest de l’Ouganda. Tous les e ´chantillons apparie ´s de parasite ´mies re ´currentes a ` Plasmodium falciparum
aux jours 7, 14, 21 et 28 apre `s traitement ont e ´te ´ ge ´notype ´s par PCR et analyse ´s pour la prote ´ine riche en glutamate (glurp) et pour les ge `nes des prote ´ines
de surface de me ´rozoı ¨te (msp1 et msp2) aﬁn de distinguer entre recrudescences et nouvelles infections. 156 (1AS ¼ 61, 3AS ¼ 35, PS seul ¼ 60) sur 199
des e ´chantillons apparie ´sd er e ´currence ont e ´te ´ entie `rement analyse ´s; 79 cas de recrudescences (1AS ¼ 32, 3AS ¼ 8, PS ¼ 39) et 77 cas de nouvelles
infections (1AS ¼ 29, 3AS ¼ 27, PS ¼ 21) ont e ´te ´ identiﬁe ´s. Les rapports des proportions entre nouvelles infections et recrudescences e ´taient de: 0,2–
0,9–1,4 et 1,9 au jours 7, 14, 21, et 28 respectivement (P < 0,001; Chi carre ´ pour le test de line ´arite ´). Des taux e ´leve ´s inattendus de nouvelles infections
ont e ´te ´ observe ´st o ˆt dans le suivi, aux jours 7 [5/26 (19,2%)] et 14 [24/51 (47,1%)]. Ces re ´sultats ont un impact signiﬁcatif sur la surveillance de la
re ´sistance et soulignent l’importance du ge ´notypage de toutes les infections re ´currentes dans les essais avec des antimalariques.
mots-cle ´s:g e ´notypage, recrudescent, re ´infections, plasmodium falciparum, malaria, the ´rapie de combinaison, ouganda
Genotipaje molecular en un ensayo de tratamiento para malaria en Uganda – una alta tasa inesperada de nuevas infecciones dentro de las dos semanas
despue ´s del tratamiento.
El genotipaje de para ´sitos de malaria mediante la reaccio ´n en cadena de la polimerasa (PCR), en ensayos de eﬁcacia de medicamentos, ayuda a diferenciar
las reinfecciones de las recrudescencias. Se condujo un ensayo de terapia de combinacio ´n de uno (n ¼ 115) o tres (n ¼ 117) dı ´as de artesunato (1AS, 3AS
4 mg/kg/dı ´a) ma ´s sulfadoxina/pirimetamina (SP) versus SP sola (n ¼ 153) en Mbarara, un a ´rea mesoende ´mica de Uganda del oeste. Todos las para-
sitemias pareadas recurrentes de Plasmodium falciparum, en los dı ´as 7, 14, 21 y 28 post tratamiento, fueron genotipadas mediante ampliﬁcacio ´n por PCR
y ana ´lisis de los genes de la proteı ´na rica en glutamato (GLURP) y las proteı ´nas de superﬁcie del merozoito (MSP) 1 y 2, con el ﬁn de distinguir infecciones
recrudescentes de nuevas infecciones. Se analizaron con e ´xito 156 (1AS ¼ 61, 3AS ¼ 35, SP solo ¼ 60) de 199 muestras pareadas, resolviendo 79 como
recrudescencias (1AS ¼ 32, 3AS ¼ 8, SP ¼ 39) y 77 como nuevas infecciones (1AS ¼ 29, 3AS ¼ 27, SP ¼ 21). La razo ´n de proporciones de nuevas
infecciones recrudescentes eran 0.2, 0.9, 1.4, y 1.9 en los dı ´as 7, 14, 21, y 28, respectivamente (P < 0.001, v
2 prueba para tendencia linear). Se observaron
unas tasas de infeccio ´n inesperadamente altas durante los primeros dı ´as de seguimiento: Dı ´a 7 [5/26 (19.2%)] y 14 [24/51 (47.1%)]. Estos resultados
impactan signiﬁcativamente sobre la monitorizacio ´n de resistencias y muestran el valor del genotipaje de todas las infecciones recurrentes en los ensayos
clı ´nicos de antimala ´ricos.
palabras clave: genotipaje, recrudescencia, re-infecciones, plasmodium falciparum, malaria, terapia de combinacio ´n, uganda
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